Spermosens
Spermosens AB is a Swedish medical device company developing JUNO-Checked, a patented biosensor diagnostic that measures sperm-egg binding via recombinant JUNO protein to predict IVF fertilization potential. It serves IVF clinics and sperm banks, pursuing commercialization through licensing partnerships across Europe, the United States, Japan, and Australia.
- Company typePublic
- Founded2018
- HeadquartersLund, Sweden
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Spermosens does
Spermosens AB (publ) is a Swedish medical device company headquartered at Medicon Village in Lund, founded in 2018 and listed on Spotlight Stock Market in Stockholm since 5 May 2021 (ticker SPERM; also tradable on Frankfurt as 9R5). The company develops JUNO-Checked, a patented diagnostic platform that measures sperm cells' functional ability to bind to the JUNO protein on human egg cells — a step in fertilization not captured by conventional semen analysis. The system combines a reusable electrochemical measurement instrument with disposable single-use biosensor chips onto which a semen sample is applied, and outputs a proprietary 'JUNO Score' intended to predict fertilization potential and guide the choice between standard IVF and ICSI. Generation 3 of the platform, designed for high-volume clinical workflows and laboratory-platform compatibility, was completed in April 2026 and is currently undergoing clinical validation at the Reproductive Medicine Center in Malmö; a prior study at the same site established a statistically significant correlation between the JUNO Score and IVF fertilization rate.
Spermosens operates a partner-driven commercialization model rather than building its own global salesforce. Future monetization is expected through licensing royalties from established Assisted Reproductive Technology market players, supported by direct research-use sales (e.g., Seattle Sperm Bank) as a stepping stone and clinical validation collaborations with leading IVF clinics. Memoranda of Understanding with Sapyen and RSI Technology Group, partnerships with Scalania AG (Europe) and ScanMed Partners (United States), and active discussions with a leading Japanese ART company structure the global rollout across Europe, the United States, Japan, and Australia. The intellectual property portfolio is protected by European Patent EP 3 768 825 (valid to 2039) with national grants in Hong Kong, Canada, Mexico, Israel, and China during 2025 and pending applications in additional jurisdictions. The company is ISO 13485:2016 compliant and is pursuing CE marking for JUNO-Checked.
As of year-end 2025 the company reported an operating loss of SEK 9.2 million (versus SEK 9.16 million in 2024) and SEK 6.8 million in cash, with no product revenue disclosed. It is led by CEO Tore Duvold, CSO Maria Liljander, CFO Alexander Dahlqvist, and Chairman Ulrik Spork; the Advisory Board includes Professors Aleksander Giwercman, Trine B. Haugen, Emir Henic, and Claus Yding Andersen. Total headcount is reported as 1–10 employees.
Spermosens firmographics
Firmographics- Name
- Spermosens
- Legal name
- Spermosens AB (publ)
- Website
- https://spermosens.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Spermosens AB is a Swedish medical device company developing JUNO-Checked, a patented biosensor diagnostic that measures sperm-egg binding via recombinant JUNO protein to predict IVF fertilization potential. It serves IVF clinics and sperm banks, pursuing commercialization through licensing partnerships across Europe, the United States, Japan, and Australia.
- Ownership category
- akta.pro rank
Spermosens industry classification
Industry- Product category
- Reproductive Medicine Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)
- akta.pro secondary industries
- Reproductive Endocrinology & Infertility (IVF/Fertility) (HLAKAJAC), Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling) (HLALAHAK)
Keywords
Where Spermosens is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
Spermosens business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Licensing royalties (planned): Future licensing income from commercial partners is expected to drive Spermosens to cash flow positivity; the SEK 10.8 million funding round in March 2025 is intended to bridge the company to this inflection point by enabling technology optimization and partnership signings.
- Research-use sales of JUNO-Checked: Early-stage sales of the device for research purposes to specialist accounts such as sperm banks (e.g., Seattle Sperm Bank) as a stepping stone toward broader commercial acceleration prior to full product launch.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels8 records
Spermosens product offering
Product offeringCore offering
Spermosens develops and manufactures JUNO-Checked, a patented diagnostic medical device platform that predicts sperm fertilization capacity by measuring the ability of sperm cells to bind to the recombinant JUNO egg-cell protein. The system pairs a reusable electrochemical measuring instrument with disposable single-use biosensor chips onto which the semen sample is applied, and outputs a quantitative "JUNO Score" intended to help clinicians and embryologists decide between standard IVF and ICSI treatment. The product is sold for research use to specialist accounts and is being commercialized globally via licensing agreements with ART market partners.
Product overview
Spermosens offers a single core product platform, JUNO-Checked, a world-first automated male fertility diagnostic medical device that assesses sperm binding capacity to the egg-cell JUNO protein to direct clinicians toward the appropriate IVF treatment (standard-IVF vs ICSI). The offering is a platform-plus-consumable architecture: the reusable measuring instrument with proprietary software analyzes single-use electrochemical biosensor chips to which semen samples are applied. The latest iteration, JUNO-Checked Generation 3, is the commercially adapted version targeting higher throughput, faster analysis, and routine laboratory compatibility, currently undergoing clinical validation at the Reproductive Medicine Center (RMC) in Malmö ahead of commercialization via licensing and partnership agreements across Europe, the US, Japan, and Australia.
Differentiator
Problem solved
Functional benefit
Brands
- JUNO-Checked: Patented, proprietary male fertility diagnostic system that measures sperm cells' ability to bind to the JUNO receptor on the egg, providing a functional assessment of fertilization capacity to assist clinicians in choosing between standard IVF or ICSI treatment.
Products and services
- JUNO-Checked Patented, user-friendly, rapid, small-footprint diagnostic system that predicts sperm fertilization capacity by measuring sperm binding to the egg-cell JUNO protein via recombinant JUNO exposure. Outputs a quantitative "JUNO Score" intended to assist clinicians and embryologists in deciding between standard IVF and ICSI treatment, and to reduce conventional IVF treatment iterations.
- JUNO-Checked Generation 3 Third-generation JUNO-Checked system developed to meet the performance standards necessary for a commercially viable product, with technical improvements aimed at supporting high-volume clinical workflows, faster analysis, higher throughput, and compatibility with routine laboratory platforms. Currently undergoing clinical validation at RMC Malmö.
- Single-use biosensor chips for JUNO-Checked Disposable electrochemical chips onto which the sperm solution is applied, used with the JUNO-Checked measuring instrument to analyze sperm binding to the egg cell as part of the JUNO-Checked system.
Quantifiable outcome
- Statistically significant positive correlation between JUNO Score and IVF fertilization rate (percentage of MII oocytes developing into 2PN zygotes)
- +3 more outcomes
Companies that use Spermosens
Customer profileNamed customers2 records
Ideal customer profiles2 records
Spermosens technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Spermosens partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- SapyencoreMemorandum of Understanding signed after the 2025 reporting period to advance partner-driven commercialization of male fertility diagnostics in global markets. The MoU positions Spermosens to leverage Sapyen's channels and capabilities for bringing JUNO-Checked to global ART market customers.
- RSI Technology GroupcoreMemorandum of Understanding signed after the 2025 reporting period to advance partner-driven commercialization of JUNO-Checked male fertility diagnostics globally. Targets global ART market access through RSI Technology Group's commercialization capabilities.
- Scalania AGcoreNewly formed partnership expected to strengthen Spermosens' regulatory and market activities in Europe for JUNO-Checked, complementing ongoing commercial-partner discussions in Europe, the US, and Japan.
- ScanMed PartnerscoreCollaboration driving business development for JUNO-Checked in the United States, in the context of Spermosens' broader active partnership discussions across the US, Europe, and Japan following positive clinical results.
- Reproductive Medicine Center (RMC) MalmöcoreClinical validation partner — RMC Malmö hosted Spermosens' statistically significant clinical study that established the correlation between JUNO Score and IVF fertilization rate (n=53 in final analysis). In April 2026, RMC Malmö initiated the Generation 3 system clinical validation study, with seven patients successfully tested to date. RMC is one of the largest IVF clinics in Sweden.
- Fram Advokatbyrå KBminorLegal advisor to Spermosens in connection with the exercise of the TO5 warrants in 2025.
- HØIBERGminorIP partner working closely with Spermosens' development team to build the patent portfolio, recognized by CSO Kushagr Punyani as a key contributor to the EPO 'Intention to Grant' notification in April 2021.
- ESHRE (European Society of Human Reproduction and Embryology)minorSpermosens holds an ESHRE Management Membership, providing engagement with the European clinical embryology and reproductive medicine community.
- Medicon Village
Scale indicators10 records
Recent moves7 records
Expansion highlights7 records
Spermosens competitors and assessment
Company assessmentBroad incumbents
- Vitrolife: Sweden-based global leader in IVF media, consumables and ART lab equipment. Directly comparable as a listed Swedish ART-diagnostics-and-consumables company targeting the same IVF clinic customer base that JUNO-Checked aims to serve.
- CooperSurgical (CooperCompanies): Major fertility and women's health diagnostics and medical device company offering sperm analysis and ART lab solutions. A natural partner or competitor for male fertility diagnostics within the global IVF clinic channel.
- Hamilton Thorne: Provider of precision instruments, consumables, and software for the ART and reproductive science markets. Comparable as a capital-equipment-plus-disposables seller to IVF clinics and a candidate licensing partner for JUNO-Checked.
- FUJIFILM Irvine Scientific: Global supplier of cell culture media, reagents, and ART products used across IVF workflows. Comparable as a large incumbent supplying consumables and instruments to the same IVF clinic channel that Spermosens targets.
Direct peers
- Genea Biomedx: Developer and manufacturer of ART lab instruments and consumables including sperm preparation and quality tools. Closely aligned product category, customer base (IVF clinics), and instrument-plus-chip business model to Spermosens.
- DxNow / Zymot (now part of CooperSurgical): Developer of the ZyMōt microfluidic sperm preparation device — a functional sperm quality/selection tool used in IVF labs. Comparable as a sperm-function diagnostic/selection device competitor within IVF clinic workflows.
Emerging players
- Mojo: Startup developing AI-powered at-home and clinical sperm quality diagnostics. Comparable as an emerging player in male fertility diagnostics with overlapping end-customers (clinics, sperm banks, patients).
- Sapyen: Male fertility diagnostic startup that has signed an MoU with Spermosens. Comparable as an emerging player in male fertility testing with overlapping product vision and shared go-to-market focus.
- Legacy (Reproductive): Male fertility testing and sperm analysis company offering both clinical and direct-to-consumer sperm quality diagnostics. Comparable as an emerging player addressing the same male infertility diagnostic gap.
- Engender Technologies: Emerging player developing sperm-sorting technologies for the ART market. Comparable as a niche player in functional male fertility technology addressing IVF laboratory workflow needs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Spermosens social profiles
Digital presenceSpermosens compliance and trust
Trust signalCompliance2 records
Spermosens financial estimates
Financial estimateRevenue estimate
Valuation estimate
Spermosens leadership team
Management profileNumber of profiles
Profiles13 records
Spermosens funding detail
Funding detailFunding overview
Funding rounds4 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Spermosens M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Spermosens
What does Spermosens do?
Spermosens develops and manufactures JUNO-Checked, a patented diagnostic medical device platform that predicts sperm fertilization capacity by measuring the ability of sperm cells to bind to the recombinant JUNO egg-cell protein. The system pairs a reusable electrochemical measuring instrument with disposable single-use biosensor chips onto which the semen sample is applied, and outputs a quantitative "JUNO Score" intended to help clinicians and embryologists decide between standard IVF and ICSI treatment. The product is sold for research use to specialist accounts and is being commercialized globally via licensing agreements with ART market partners.
Is Spermosens a public or private company?
Spermosens is a public company. It is classified as public and is currently operating.
When was Spermosens founded?
Spermosens was founded in 2018. It employs 1 to 10 people.
Where is Spermosens based?
Spermosens is headquartered in Lund, Sweden, in the Europe region.
How does Spermosens make money?
Two revenue lines are on record. Licensing royalties (planned) is the primary driver. The others are research-use sales of JUNO-Checked.
Who are Spermosens's main competitors?
Broad incumbents on record are Vitrolife, CooperSurgical (CooperCompanies), Hamilton Thorne and FUJIFILM Irvine Scientific. Direct peers are Genea Biomedx and DxNow / Zymot (now part of CooperSurgical). Emerging players are Mojo, Sapyen, Legacy (Reproductive) and Engender Technologies.
Does Spermosens have an API?
No public API is recorded for Spermosens.
What industry is Spermosens in?
Spermosens's product category is Reproductive Medicine Diagnostics. Its primary akta.pro industry code is HLAAALAJ, Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening), with a secondary code of HLAKAJAC, Reproductive Endocrinology & Infertility (IVF/Fertility). Its NAICS code is 541714 and its SIC code is 2835.